Company Product Description Indication Status
Astrazeneca plc, of Cambridge, U.K. Imfinzi (durvalumab) Monoclonal antibody targeting PD-L1 Non-small-cell lung cancer and bladder cancer FDA granted priority review for a new 4-week, fixed-dose regimen
Emmaus Life Sciences Inc., of Torrance, Calif. Endari  L-glutamine oral powder Sickle cell disease  Submitted an MAA to the Saudi Food and Drug Authority
Immatics NV, of Tuebingen, Germany IMA-203 Targets peptides derived from preferentially expressed antigen in melanoma Solid tumors expressing preferentially expressed antigen in melanoma Germany's Paul-Ehrlich-Institute approved the CTA for a phase I study
Kimera Labs Inc., of Miramar, Fla. Xoglo Isolated placental mesenchymal stem cell-based exosomes Acute respiratory distress syndrome secondary to COVID-19 infection Filed an IND application with the FDA 
Krystal Biotech Inc., of Pittsburgh, Pa. KB-407 Inhaled, repeat-dose gene therapy product Cystic fibrosis Granted orphan drug designation by the FDA 

Notes

For more information about individual companies and/or products, see Cortellis.